Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, in Participants with Ovarian Cancer

    Cancer Categories
    • Gynecologic
    Karmanos Trial ID
    • 2025-088
    NCT ID
    • NCT07226427
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Ira
      Winer, M.D., Ph.D., FACOG

      Oncology - Gynecologic, Oncology - Surgical View Profile

    Objective:

    Primary Objectives:

    • Part A: To identify the maximum tolerated dose (MTD)/ maximum administrated dose (MAD) and recommended expansion doses for MEN2501 in platinum-resistant ovarian cancer
    • Part B: Establish the recommended phase 2 dose (RP2D) of MEN2501

    Secondary Objectives:

    • Evaluate the safety and tolerability of MEN2501
    • To evaluate preliminary antitumor activity of MEN2501.
    • Characterize the PK profile of MEN2501 in plasma and urine and evaluate the effect of food on the PK when administered
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions